<DOC>
	<DOCNO>NCT00686517</DOCNO>
	<brief_summary>The objective study evaluate efficacy three regimen pegylated interferon-alfa 2b ( PEG-IFN ) either monotherapy combination ribavirin participant acute hepatitis C. After 12 week observation disease onset , participant receive one follow regimen : ( 1 ) 24-week course PEG-IFN monotherapy ( PEG-IFN 24 ) ; ( 2 ) 12-week course PEG-IFN monotherapy ( PEG-IFN-12 ) ; ( 3 ) 12-week course PEG-IFN combination ribavirin ( PEG-IFN + RVB 12 ) . After treatment period , participant enter 12-month follow-up .</brief_summary>
	<brief_title>Evaluation Peginterferon Alfa-2b Monotherapy Combination With Ribavirin Participants With Acute Hepatitis C ( P03552/MK-4031-137 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Diagnosed acute hepatitis C virus ( HCV ) . Normal Elevated serum alanine transferase ( ALT ) level Positive serum HCVRNA . Aged 18 65 year . Negative urine serum pregnancy test ( woman childbearing potential ) document within 24hour period prior first dose drug . Additionally , fertile male partner childbearing age female must use reliable contraception study additionally participant treat ribavirin , 6 month ( woman ) 7 month ( man partner ) treatment completion Liver disease unrelated HCV infection Hemoglobin ( Hgb ) &lt; 12g/dL woman &lt; 13g/dL men ; white blood cell ( WBC ) &lt; 3,000/uL ; platelet ( PLTs ) &lt; 100,000/ul Women ongoing pregnancy breast feed History severe psychiatric disease , especially depression History neurologic disease , especially epilepsy History evidence symptom severe cardiac , gastrointestinal kidney disease Positive antiHuman Immunodeficiency Virus ( HIV ) antibodies Positive antinuclear antibody ( ANA ) and/or AntiSmooth Muscle Antibody ( ASMA ) ( &gt; 1/80 ) Positive Hepatitis B surface antigen ( HBsAg ) History receive systemic antineoplastic immunomodulatory treatment previous 6 month History evidence severe illness condition would make participant , opinion investigator , unsuitable study ( active drug addict except methadone treatment , thalassemic , dyalized include )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>